CN is believing

Tell us about CN Bio’s approach
Through our organ-on-a-chip (OOC) technology and services, CN Bio aims to provide the pharmaceutical industry with human-relevant data to inform decisions about the right new medicines to progress into the clinic. We believe this is key to addressing inefficiencies in the drug discovery process and bringing new treatments to patients more rapidly and at lower cost.

How do you expect drug development to improve through innovation?
I see a combination of AI and big clinical/non-clinical data sets driving novel targets, which will increasingly be addressed with non-small molecule modalities. In the preclinical space, there are a host of new technologies for disease modelling, ADME (Absorption, Distribution, Metabolism and Excretion) and toxicology. Furthermore, OOC and organoids provide a richer, more relevant understanding of new drug performance.

How will patient involvement in new therapies evolve?
Particularly for rare diseases, I see the increasing involvement of charities and patient advocacy groups as an important enabler of clinical trials.

Which of your projects are you most excited by?
I see our PhysioMimix OOC assay for Non-Alcoholic Steatohepatitis, as a game changer. In 2022, this will be available as a product for pharma companies to deploy in their own labs for the first time. To date, the clinic has been a graveyard for anti-NASH compounds and combinations whereas our assay can provide scientists with insights into disease, yielding data which allows smarter and faster progression.

What are your ambitions for the year ahead?
To see organ-on-a-chip technologies being widely adopted across pharma and their power to influence decisions being exemplified through the inclusion of OOC data.

Go to cn-bio.com